GOLDRED NANOBIOTECH CO., LTD.
Update：2026/11/10
Industries
Main Industry
Consumer Goods
Main Product/Service
Golden Biotechnology Corporation is researching methods and compositions for treating RNA virus-induced diseases using cyclohexenone compounds. This aligns with their focus on developing novel therapeutic agents to address unmet medical needs, particularl
The content above was translated by Ai
Founded Year
2011
Unified Business No.
53633736
Status
Active
Number of Employees
0
Total Paid-in
Capital
27,500,000 (NT$)
Location of Company
Taiwan
, Taoyuan City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Golden Biotechnology Corporation (GBC) is an Advanced Drug Development Company with an established Team that have a proven track record in Clinical Development, Regulatory Affairs & Commercialization.
GBC is focused on the clinical development of new therapeutic agents that can meet the needs of patients with of High Unmet Medical Needs.
Antroquinonol is an innovative compound discovered by the GBC Team with excellent Efficacy and Safety Profile. Antroquinonol have completed a number of Phase 1 and 2 studies in difficult to treat indications – Oncology and Infectious Diseases.
GBC’s looks excitedly to the future to solve the hardest questions on Antroquinonol to ultimately benefit patients and healthcare professionals.
GBC is focused on the clinical development of new therapeutic agents that can meet the needs of patients with of High Unmet Medical Needs.
Antroquinonol is an innovative compound discovered by the GBC Team with excellent Efficacy and Safety Profile. Antroquinonol have completed a number of Phase 1 and 2 studies in difficult to treat indications – Oncology and Infectious Diseases.
GBC’s looks excitedly to the future to solve the hardest questions on Antroquinonol to ultimately benefit patients and healthcare professionals.
The content above was translated by Ai
